Japan Early Diabetes Intervention Study (JEDIS)

Japan Early Diabetes Intervention Study Group

Status: Unknown

Conditions: Diabetes Mellitus

Treatments: Drug: Lifestyle guidance and monotherapy with gliclazide; Behavioral: Standard lifestyle guidance; Drug: Lifestyle guidance and monotherapy with acarbose; Drug: Lifestyle guidance and monotherapy with metformin

Study type: Interventional

Funder types: Other

Identifiers

NCT00464594

UMIN000000681

JEDIS ver.4.0

Details and patient eligibility

About

The purpose of this study is to compare the suppressive effect of two kinds of interventions on the worsening/progression to definite diabetes: standard lifestyle guidance and standard lifestyle guidance combined with pharmacological intervention (monotherapy with one of acarbose, metformin, or gliclazide).

Full description

In newly-diagnosed early diabetes patients, a randomized comparative study will be conducted to compare the suppressive effect of the following two kinds of interventions on the worsening/progression to definite diabetes which has a harmful hyperglycemia i.e. an increased risk of microangiopathy: standard education for the improvement of lifestyle in accordance with the "Guidelines for the Treatment of Diabetes Mellitus in Japan" of the Japan Diabetes Society (JDS) and standard lifestyle guidance combined with pharmacological intervention using the lowest possible dose of commercially available oral hypoglycemic agents (one of acarbose, metformin, or gliclazide) in Japan.

Sex: All

Ages: 30 to 69 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Results of 75-g oral glucose tolerance test (75 g OGTT)will be used to confirm FPG <= 125 mg/dL, 2-h PG >= 200 mg/dL and HbA1c <= 6.9%

Exclusion criteria

• Type 1 diabetes mellitus
• Undergoing treatment with steroids
• Secondary diabetes mellitus
• Diabetes mellitus due to suspected gene abnormalities
• BMI >= 35 kg/m2 or BMI < 18.5 kg/m2
• Undergone a surgery
• Severe hyperuricemia (gout) associated with organ dysfunction
• Severe vascular diseases with organ dysfunction
• Cancer or other malignant neoplasms
• Liver cirrhosis or chronic hepatic, chronic renal failure
• Gastrointestinal disorders
• Always performing rigorous muscular exercise
• Severe infection or serious trauma
• Women who are pregnant
• Alcohol dependence or drug dependence
• Drug allergy
• Anemic
• Abnormal hemoglobinuria
• Severe mental disease

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)